Measuring the biomechanical properties of tissues using OCT Vibrography

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop OCT Vibrography, also known as OCT elastography, as a new method for assessing the biomechanical properties of human tissues in vivo. The researchers will establish baseline data from healthy subjects and compare the elastic moduli of different tissue types, particularly focusing on keratoconus versus normal eyes. The findings could enhance the understanding of how tissue microstructure relates to its mechanical properties, potentially improving the diagnosis and treatment of conditions like keratoconus and inflammatory skin and gingival diseases. The technology may also have broader applications beyond the specific tissues studied.

Why it matters

Who can join: the full rules

Group 1:

Inclusion criteria:

• Subjects with healthy eyes (age 18 - 75, N = 50)

Exclusion criteria:

* Subjects with history of eye diseases, and previous eye surgeries.
* Subjects with diabetes, glaucoma family history
* Subjects allergic to anesthetic eyedrop, especially proparacaine
* Subjects with severe allergy
* Subjects who have difficulty biting
* Subjects who have recurrent corneal erosion

Group 2:

Inclusion criteria:

• Subjects with healthy skin (age 18 - 75, N = 10)

Exclusion criteria:

• Subjects with open cuts/sores on the skin, skin infection, or any contagious skin condition

Group 3:

Inclusion criteria:

• Subjects with healthy gingiva (age 18 - 75, N = 10)

Exclusion criteria:

• Subjects with open cuts/sores on the gingiva, gingiva infection, or any contagious gingiva condition

Group 4:

Inclusion criteria:

• Mild or moderate keratoconus subjects (age 18 - 40, N = 20)

Exclusion criteria:

• Subjects with K-max above 60 diopters (Pentacam imaging) are excluded

Where it's running

• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Seok-Hyun Yun, PhD — Massachusetts General Hospital
• Study coordinator: Jing Zhang, PhD
• Email: jzhang110@mgh.harvard.edu
• Phone: 6173730127

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does driving with UVA exposure affect facial skin hydration on the left vs right cheek in Florida drivers

  This observational study tests whether Florida women who drive more show less hydration on their left cheek (exposed to UVA through the driver-side window) compared with their right cheek.

  Recruiting IAS Skin Care · Orlando, Florida · NCT07764809

• Topical KB111 for Hailey-Hailey Disease (early phase, kids and adults)

  This study tests whether a topical KB111 treatment is safe and helps with lesions in people with Hailey-Hailey disease, including adolescents and adults.

  Recruiting Early Phase 1 Krystal Biotech, Inc. · Miami, Florida · NCT07717346

• GLP-1 receptor agonists and dry eye in adults with type 2 diabetes and obesity

  This study tests whether GLP-1 receptor agonists affect dry eye disease in adults with type 2 diabetes and obesity.

  Recruiting Attikon Hospital · Athens · NCT07605572

• Turning anonymous symptom descriptions into structured biological signals with OpenGenome

  This project tries to turn adults' anonymous free-text symptom descriptions submitted to OpenGenome into structured, literature-grounded biological signals using PubMed and ClinicalTrials.gov sources and a constrained reasoning model.

  Recruiting OpenGenome · Friedrichshain, State of Berlin · NCT07578610

• JAK1 and JAK2 activation in healthy versus inflamed gums

  We will test whether the JAK1 and JAK2 immune-signaling pathways are more active in adults with periodontitis than in adults with healthy gums.

  Recruiting University of Chile · Santiago, Metropolitan Region · NCT07536204

• Safety of BG-A3004 in healthy volunteers and people with immune-mediated skin diseases

  This study will test whether single and multiple doses of the experimental drug BG-A3004 are safe and how the body handles it in healthy adults and people with immune-mediated skin diseases.

  Recruiting at 11 sites Phase 1 BeOne Medicines · Beijing, Beijing Municipality and 10 other locations · NCT07412691

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.